Resources for Health Care Professionals
Resources for Health Care Professionals
This web- and mobile-optimized resource provides high-quality, relevant and trusted medical information essential for health care practice. The site features breaking medical news, accredited education courses and tools tailored by medical specialty and clinician need. Additionally, a point-of-care mobile application is available in key markets. Over 3.6 million health care professionals are registered members of Univadis, which is available across 63 specialties, 20 languages and 90 geographic markets.
The medical and scientific content comes from independent third parties, such as scientific leaders, educational institutions and medical societies, as well as through partnerships with a range of world-leading medical publishers. Sponsor organizations provide educational funding to expand and augment the site’s core content in adherence with the strict editorial principles of independence, relevance and quality.
Univadis is available across 63 specialties, in 20 languages and in 90 geographic markets
With no subscription or registration fees, Univadis provides access to:
- The latest medical news and clinical developments in 60+ specialist areas
- Selected full-text articles from The Lancet and JAMA
- Weekly research summaries from major peer-reviewed publications
- Conference coverage from medical congresses
- Full online access to trusted medical references
- A library of thousands of medical images to enrich presentations and research
- A wide range of resources to enhance interactions with patients at the point of care, including interactive 3-D anatomy tools and patient handouts
Univadis creates unique opportunities for long-term and meaningful partnerships with scientific and health care organizations, in addition to the world-class publishers that our company already works with. Univadis aims to be a valuable partner in building lasting relationships with our 3.6 million individual health care users globally.
Antimicrobial Stewardship (AMS) is a rational, systematic approach to the use of antimicrobials in order to optimize patient outcomes and population health, and minimize unintended consequences, such as selection of pathogenic organisms (e.g., Clostridium difficile), toxicity and resistance. Our AMS vision is to be known as a leader within the industry and a sought-after partner within the broader health care community in advancing patient-centered AMS through education, implementation, research and advocacy initiatives with an emphasis on patient outcomes, population health and value of care. We made significant progress toward this goal in 2016.
Education is foundational to AMS, and our company has helped support a variety of educational offerings for health care providers through international, national, regional and state organizations, including those with an infectious diseases–based membership as well as other subspecialty and generalist organizations (e.g., Society for Hospital Medicine, American Society of Health System Pharmacists). Additionally, we are supporting the development and implementation of web- and in-clinic-based patient education strategies on AMS and antimicrobial resistance (AMR) for the urgent-care setting in order to improve health literacy regarding AMR/AMS and patient satisfaction when antibiotics are not needed.
Outside the United States, we provide preceptorships and workshops for health care providers to learn firsthand from other providers practicing AMS. We also supported the development and continue to support the maintenance of a comprehensive, high-quality AMS web resource that engages a diverse, international audience and covers topics related to clinical practice, infection control and prevention, policy, clinical research and animal health. Learn more.
Implementation is required for AMS action and impact. We participated in the expert panel to develop the National Quality Forum (NQF) “Antibiotic Stewardship in Acute Care: A Practical Playbook,” which provides practical guidance on options for hospitals and acute care facilities to take action using their existing resource availability. The Playbook was launched in May 2016 via a webinar with approximately 1,100 attendees—the most well-attended NQF webinar to date. Since launch, the Playbook has been downloaded over 30,000 times. Outside the United States, our company has an ongoing collaboration with an AMS Center of Excellence in Cali, Colombia that has trained over 200 physicians across Latin America and implemented over 70 local hospital protocols.
Research is needed to build and disseminate evidence regarding AMS best practices and their impact on patients and population health. A two-year collaborative project with the CDC and the CDC Foundation to develop standardized metrics and an outcomes assessment tool for AMS programs related to patient safety and quality of care will be completed in 2017.
Our company also supports an investigator-initiated research grant program specific to AMS and has invested over $1.5M to support 18 studies since 2013. Additionally, we provided support for the development of an annual, two-day research conference implemented by the Society for Healthcare Epidemiology of America, with a goal of improving the quality of AMS research. In 2016, approximately 150 health care providers attended the inaugural conference.
Advocacy for continued antimicrobial innovation, appropriate AMS and sustainable access is vital to the fight against antimicrobial resistance. We are active in a number of policy and legislative discussions and initiatives, and have several representatives on the European Innovative Medicines Initiative (IMI) Driving reinvestment in research and development and responsible antibiotic use (DRIVE-AB) work packages.
DRIVE-AB is tasked with defining the responsible use of antibiotics, identifying the antibiotic-related population health priorities, calculating the societal value of having new antibiotics available for these priorities and developing economic models to promote the desired antibiotic innovation and the sustainable use of the resulting, novel antibiotics. The final recommendations from the DRIVE-AB initiative will be released in September 2017.
We also are providing support to the Global Antibiotic Resistance Partnership (GARP) to assist low- and middle-income countries in developing country-led national action plans for AMR in support of the World Health Organization goals. The GARP will result in:
- Situation analyses of human and animal antibiotic use and resistance, infectious disease burden, health indicators, pharmaceutical supply chain and pertinent regulations
- Individualized national action plans
- Implementation plans for each country involved
Lastly, we developed a Global AMR Action Plan to demonstrate our commitment to address antimicrobial resistance.